HRP20190089T1 - Vortioksetin piroglutamat - Google Patents

Vortioksetin piroglutamat

Info

Publication number
HRP20190089T1
HRP20190089T1 HRP20190089TT HRP20190089T HRP20190089T1 HR P20190089 T1 HRP20190089 T1 HR P20190089T1 HR P20190089T T HRP20190089T T HR P20190089TT HR P20190089 T HRP20190089 T HR P20190089T HR P20190089 T1 HRP20190089 T1 HR P20190089T1
Authority
HR
Croatia
Prior art keywords
vortioxetine pyroglutamate
vortioxetine
pyroglutamate
Prior art date
Application number
HRP20190089TT
Other languages
English (en)
Inventor
Heidi Lopez De Diego
Kim Lasse Christensen
René HOLM
Jens Kateb
Original Assignee
H. Lundbeck A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55963369&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20190089(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H. Lundbeck A/S filed Critical H. Lundbeck A/S
Publication of HRP20190089T1 publication Critical patent/HRP20190089T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2732-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D207/282-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HRP20190089TT 2015-05-13 2019-01-16 Vortioksetin piroglutamat HRP20190089T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201500284 2015-05-13
PCT/EP2016/060540 WO2016180870A1 (en) 2015-05-13 2016-05-11 Vortioxetine pyroglutamate
EP16721817.1A EP3294719B1 (en) 2015-05-13 2016-05-11 Vortioxetine pyroglutamate

Publications (1)

Publication Number Publication Date
HRP20190089T1 true HRP20190089T1 (hr) 2019-02-22

Family

ID=55963369

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20190089TT HRP20190089T1 (hr) 2015-05-13 2019-01-16 Vortioksetin piroglutamat

Country Status (43)

Country Link
US (2) US10287261B2 (hr)
EP (1) EP3294719B1 (hr)
JP (1) JP6731001B2 (hr)
KR (1) KR102551429B1 (hr)
CN (1) CN107567440B (hr)
AR (1) AR104591A1 (hr)
AU (1) AU2016259762B2 (hr)
BR (1) BR112017024039B8 (hr)
CA (1) CA2984615C (hr)
CL (1) CL2017002844A1 (hr)
CO (1) CO2017011295A2 (hr)
CR (1) CR20170506A (hr)
CY (1) CY1121171T1 (hr)
DK (1) DK3294719T3 (hr)
DO (1) DOP2017000260A (hr)
EA (1) EA032363B1 (hr)
EC (1) ECSP17074919A (hr)
ES (1) ES2709362T3 (hr)
GE (1) GEP20197020B (hr)
HK (1) HK1252099B (hr)
HR (1) HRP20190089T1 (hr)
HU (1) HUE042893T2 (hr)
IL (1) IL255466B (hr)
JO (1) JO3456B1 (hr)
LT (1) LT3294719T (hr)
MA (1) MA43397A (hr)
ME (1) ME03312B (hr)
MX (1) MX2017014390A (hr)
MY (1) MY184965A (hr)
PE (1) PE20180039A1 (hr)
PH (1) PH12017502028A1 (hr)
PL (1) PL3294719T3 (hr)
PT (1) PT3294719T (hr)
RS (1) RS58263B1 (hr)
RU (1) RU2713889C2 (hr)
SI (1) SI3294719T1 (hr)
SV (1) SV2017005560A (hr)
TN (1) TN2017000453A1 (hr)
TR (1) TR201901228T4 (hr)
TW (1) TWI700276B (hr)
UA (1) UA120779C2 (hr)
WO (1) WO2016180870A1 (hr)
ZA (1) ZA201707337B (hr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3026728A1 (en) 2016-07-01 2018-01-04 H. Lundbeck A/S Vortioxetine dosing regimes for fast onset of antidepressant effect
US10519121B2 (en) 2016-12-30 2019-12-31 Apicore Us Llc Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts
US11020390B2 (en) * 2017-02-17 2021-06-01 Unichem Laboratories Ltd Bioequivalent pharmaceutical composition of vortioxetine hydrobromide
PL3532457T3 (pl) * 2017-07-31 2020-10-19 Small Pharma Ltd Postacie krystaliczne hydroksynorketaminy
GB201715950D0 (en) * 2017-10-02 2017-11-15 Croda Int Plc Gel composition comprising a phase change material
WO2021198778A1 (en) 2020-04-03 2021-10-07 H. Lundbeck A/S 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine for prevention or treatment of emotional blunting

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1006728A (en) * 1962-12-31 1965-10-06 Mundipharma Ag Amine salts of pyrrolidone carboxylic acid
JPS6160620A (ja) 1984-09-03 1986-03-28 Teijin Ltd ピログルタミン酸エステル類を含有する医薬品組成物
US4780667A (en) 1985-06-25 1988-10-25 Hewlett-Packard Company Magnetostatic wave delay line discriminator with automatic quadrature setting and automatic calibration
FR2694194B1 (fr) 1992-07-31 1994-11-04 Health Business Dev Gel hydratant, médicament et composition cosmétique le contenant, procédé de préparation dudit gel.
US6709678B2 (en) 1996-08-15 2004-03-23 Losan Pharma Gmbh Easy to swallow oral medicament composition
US6436946B1 (en) * 1997-05-02 2002-08-20 Morris A. Mann Xanthine-containing compositions for oral administration and uses related thereto
SK284948B6 (sk) 2000-04-06 2006-03-02 Zentiva, A. S. Liečivý prípravok s obsahom vápnika alebo zmesi vápnika a vitamínu D, alebo zmesi vápnika a horčíka v novej liekovej forme
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
DK2258349T3 (da) 2004-05-11 2014-10-13 Egalet Ltd Kvældbar doseringsform omfattende gellangummi
MX2008016141A (es) * 2006-06-16 2009-02-04 Lundbeck & Co As H 1-[2-(2,4-dimetilfenilsulfanil)-fenil] piperazina como un compuesto con actividad combinada de recaptación de serotonina, 5-ht3 y 5-ht1a.para el tratamiento de daño cognitivo.
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
WO2010121621A1 (en) 2009-04-24 2010-10-28 H. Lundbeck A/S Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
DK2470166T3 (da) * 2009-08-24 2013-09-08 Lundbeck & Co As H Nye sammensætninger af 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazin
MY162392A (en) 2010-04-30 2017-06-15 Takeda Pharmaceuticals Co Enteric tablet
EP2897943B1 (en) * 2012-09-19 2019-04-24 Sandoz AG Crystalline form of vortioxetine hydrobromide
DK2958903T3 (en) 2013-02-22 2017-05-15 H Lundbeck As METHOD OF PREPARING VORTIOXETIN

Also Published As

Publication number Publication date
PL3294719T3 (pl) 2019-04-30
TN2017000453A1 (en) 2019-04-12
MY184965A (en) 2021-04-30
EP3294719A1 (en) 2018-03-21
DK3294719T3 (en) 2019-02-25
MX2017014390A (es) 2018-03-23
TWI700276B (zh) 2020-08-01
CA2984615C (en) 2023-06-13
DOP2017000260A (es) 2018-02-28
TW201706255A (zh) 2017-02-16
US10287261B2 (en) 2019-05-14
HK1252099B (zh) 2020-02-07
ECSP17074919A (es) 2018-02-28
US20160368884A1 (en) 2016-12-22
SV2017005560A (es) 2018-02-23
RU2017139002A3 (hr) 2019-08-30
JP6731001B2 (ja) 2020-07-29
MA43397A (fr) 2018-03-21
GEP20197020B (en) 2019-09-25
IL255466B (en) 2022-07-01
CA2984615A1 (en) 2016-11-17
RU2017139002A (ru) 2019-06-13
AR104591A1 (es) 2017-08-02
PT3294719T (pt) 2019-02-07
EA201792262A1 (ru) 2018-04-30
US20190210987A1 (en) 2019-07-11
ME03312B (me) 2019-10-20
IL255466A (en) 2018-01-31
UA120779C2 (uk) 2020-02-10
CO2017011295A2 (es) 2018-02-20
RU2713889C2 (ru) 2020-02-10
LT3294719T (lt) 2019-02-11
HUE042893T2 (hu) 2019-07-29
US11279682B2 (en) 2022-03-22
SI3294719T1 (sl) 2019-03-29
PE20180039A1 (es) 2018-01-09
KR102551429B1 (ko) 2023-07-04
EA032363B1 (ru) 2019-05-31
AU2016259762A1 (en) 2017-11-16
BR112017024039B8 (pt) 2023-10-31
KR20180006909A (ko) 2018-01-19
EP3294719B1 (en) 2019-01-02
TR201901228T4 (tr) 2019-02-21
CY1121171T1 (el) 2020-05-29
PH12017502028A1 (en) 2018-04-02
CN107567440A (zh) 2018-01-09
ES2709362T3 (es) 2019-04-16
CL2017002844A1 (es) 2018-05-11
BR112017024039B1 (pt) 2023-07-04
HK1252099A1 (zh) 2019-05-17
CN107567440B (zh) 2021-06-22
WO2016180870A1 (en) 2016-11-17
BR112017024039A2 (pt) 2018-07-24
RS58263B1 (sr) 2019-03-29
CR20170506A (es) 2018-02-08
AU2016259762B2 (en) 2020-03-19
JP2018515520A (ja) 2018-06-14
ZA201707337B (en) 2019-02-27
JO3456B1 (ar) 2020-07-05

Similar Documents

Publication Publication Date Title
SG11201705976UA (en) Cryoneedle
HRP20190089T1 (hr) Vortioksetin piroglutamat
HK1251001A1 (zh) Il-37變體
AU361999S (en) Ballustrade
PL3124119T3 (pl) Odkiełkownica
DK3133099T3 (en) Polymermodificeret polyoldispersion
DK3250312T3 (en) Urea-metalnitrat-scr-system
GB201516249D0 (en) Liqui-glove
DK3242882T3 (en) Cgrp-antagonistpeptider
RS63420B1 (sr) Peg-vezivo
GB201617732D0 (en) Corbel-Pro
AU5516P (en) LEP08 Lepidosperma squamatum
GB201522365D0 (en) Concept abcd12
AU5511P (en) PTK647 Epichloe coenophiala
GB201518520D0 (en) Concept ABCD4
AU366552S (en) Nutblock
GB201520298D0 (en) Thingy
AU367131S (en) USB-charger
GB201517693D0 (en) Buggys
GB201515216D0 (en) Concept B
GB201516942D0 (en) Flightpal
GB201516026D0 (en) Rencu
GB201515793D0 (en) Dartboards
GB201506176D0 (en) Concept concept
AU365008S (en) Playsuit